In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair ...

In the landmark CLEOPATRA study (NCT00567190), THP significantly improved median overall survival (OS) from 40.8 months (95% CI, 35.8-48.3) with placebo, trastuzumab, and docetaxel to 56.5 months ...

Nadal-Melsió could not immediately be reached for comment on Monday. The museum said her position “will not be maintained” over the next year during the program’s suspension.

CHICAGO — Second-line trastuzumab deruxtecan-nxki significantly extended OS compared with paclitaxel plus ramucirumab for patients with advanced gastric cancers previously treated with ...

Background: Trastuzumab deruxtecan (T-DXd) is a novel antibody-drug conjugate (ADC) showing significant promise in treatment of metastatic HER2+ and HER2-low breast cancer. This systematic review and ...

4 Van Cutsem E. et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a ...

Topline data were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki followed by THP in patients with high-risk, locally advanced HER2-positive early stage breast cancer.

Introduction: Trastuzumab deruxtecan (T-DXd) is used to treat human epidermal growth factor receptor 2-positive breast cancer, non-small cell lung cancer, and gastric cancer, with reports of favorable ...

Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab demonstrated ...

In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate ...

In this issue of The Lancet Oncology, another phase 2 trial conducted exclusively in China with a different HER2-targeted antibody–drug conjugate as the palliative second-line treatment of NSCLC is ...

ASCO GU 2025, Bladder Cancer, Targeting Bladder Cancer with Antibody Drug Conjugates, EV-301 trial, TROPiCS-04 trial, KEYNOTE-A39 trial, enfortumab vedotin, sacituzumab govitecan, trastuzumab ...